Variable

Number of cases

Age (years)

 

 Means ± standard deviation

57 ± 10

 Range

32 – 75

Gender (M/F) 47 (87.0%)/ 7 (13.0%)
Etiology
HBV
HCV
Alcohol
Idiopathic
38 (70.3%)
6 (11.1%)
7 (13.0%)
3 (5.6%)
Type of tumor
Massive Diffuse
Diffuse
Multi-nodular
Single
32 (59.3%)
13 (24.1%)
9 (16.7%)
0 (0%)
PVTT
Yes
No
40 (74.1%)
14 (25.9%)
Grade of PVTT
Vp0
Vp1
Vp2
Vp3
Vp4
14 (25.9%)
0 (0%)
6 (11.1%)
16 (29.6%)
18 (33.3%)
Child-Pugh Class A / B /C 33 (61.1%)/ 17 (31.5%)/ 4 (7.4%)
Albumin (g/dL)
≥ 3.5 / 〈 3.5 21 (38.9%)/ 33 (61.1%)
Bilirubin (mg/dL)
≤ 1.2 / 〉 1.2 23 (42.6%)/ 31 (57.4%)
PT (INR)
≤ 1/ 〉 1 8 (14.8%)/ 46 (85.2%)
ALT (U/I)
≤ 40 / 〉 40 28 (51.9%)/ 26 (48.1%)
AFP (ng/mL)
≥ 200
〈200
33 (61.1%)
21 (38.9%)
Ascites
No/Well controlled/Poor controlled

42 (77.8%)/ 9 (16.7%)/ 2 (3.7%)

Previous treatment
Transcatheter arterial chemoembolization
Percutaneous ethanol injection
24 (88.9%)
2 (7.4%)
1 (3.7%)

Operation
Follow-up period (days)

119 (52 – 1537)
51/ 54 (94.4%)

Median (range)
NO. decreased patients
HBV: Hepatitis B Virus; HCV: Hepatitis C Virus; PVTT: Portal Vein Tumor Thrombosis; Vp0: Absence of invasion of (or tumor thrombus in) the portal vein; Vp1: Invasion (or tumor thrombus in) distal to the second order branches of the portalvein, but not of the second order branches; Vp2: Invasion of (or tumor thrombus in) second order branches of the portal vein; Vp3: Invasion of (or tumor thrombus in) first order branches of the portal vein; Vp4: Invasion of (or tumor thrombus in) the main trunk of the portal veinand/or contra-lateral portal vein branch to the primarily involved lobe; PT: Prothrombin Time; INR: International Normalized Ratio; ALT: Alanine Transaminase: AFP: Alpha-fetoprotein; HAIC: Hepatic Arterial Infusion Chemotherapy; 5-FU: Fluorouracil
Table 1: Baseline Characteristics of Patients.